Literature DB >> 16984210

Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Mei-Ling Chen1.   

Abstract

Ethnic or racial differences in pharmacokinetics and pharmacodynamics have been attributed to the distinctions in the genetic, physiological and pathological factors between ethnic/racial groups. These pharmacokinetic/pharmacodynamic differences are also known to be influenced by several extrinsic factors such as socioeconomic background, culture, diet and environment. However, it is noted that other factors related to dosage regimen and dosage form have largely been ignored or overlooked when conducting or analysing pharmacokinetic/pharmacodynamic studies in relation to ethnicity/race. Potential interactions can arise between the characteristics of ethnicity/race and a unique feature of dosage regimen or dosage form used in the study, which may partly account for the observed pharmacokinetic/pharmacodynamic differences between ethnic/racial groups. Ethnic/racial differences in pharmacokinetics/pharmacodynamics can occur from drug administration through a specific route that imparts distinct pattern of absorption, distribution, transport, metabolism or excretion. For example, racial differences in the first-pass metabolism of a drug following oral administration may not be relevant when the drug is applied to the skin. On the other hand, ethnic/racial difference in pharmacokinetics/pharmacodynamics can also happen via two different routes of drug delivery, with varying levels of dissimilarity between routes. For example, greater ethnic/racial differences were observed in oral clearance than in systemic clearance of some drugs, which might be explained by the pre-systemic factors involved in the oral administration as opposed to the intravenous administration. Similarly, changes in the dose frequency and/or duration may have profound impact on the ethnic/racial differences in pharmacokinetic/pharmacodynamic outcome. Saturation of enzymes, transporters or receptors at high drug concentrations is a possible reason for many observed ethnic/racial discrepancies between single- and multiple-dose regimens, or between low- and high-dose administrations. The presence of genetic polymorphism of enzymes and/or transporters can further complicate the analysis of pharmacokinetic/pharmacodynamic data in ethnic/racial populations. Even within the same dosage regimen, the use of different dosage forms may trigger significantly different pharmacokinetic/pharmacodynamic responses in various ethnic/racial groups, given that different dosage forms may exhibit different rates of drug release, may release the drug at different sites, and/or have different retention times at specific sites of the body. It is thus cautioned that the pharmacokinetic/pharmacodynamic data obtained from different ethnic/racial groups cannot be indiscriminately compared or combined for analysis if there is a lack of homogeneity in the apparent 'extrinsic' factors, including dosage regimen and dosage form.

Mesh:

Substances:

Year:  2006        PMID: 16984210     DOI: 10.2165/00003088-200645100-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  73 in total

1.  Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

Authors:  Shinji Tatami; Norio Yamamura; Akiko Sarashina; Chan-Loi Yong; Takashi Igarashi; Yusuke Tanigawara
Journal:  Drug Metab Pharmacokinet       Date:  2004-02       Impact factor: 3.614

Review 2.  Influence of race or ethnicity on pharmacokinetics of drugs.

Authors:  J A Johnson
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

3.  Racial differences in breast carcinoma survival.

Authors:  S A Joslyn; M M West
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

Review 4.  Racial differences in skin pathophysiology.

Authors:  E Berardesca; H Maibach
Journal:  J Am Acad Dermatol       Date:  1996-04       Impact factor: 11.527

5.  Bowel function measurements of individuals with different eating patterns.

Authors:  G J Davies; M Crowder; B Reid; J W Dickerson
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

6.  Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism.

Authors:  C Hoyo-Vadillo; G Castañeda-Hernández; J E Herrera; J Vidal-Gárate; A Moreno-Ramos; F Chávez; E Hong
Journal:  J Clin Pharmacol       Date:  1989-09       Impact factor: 3.126

7.  CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.

Authors:  J A Johnson; V L Herring; M S Wolfe; M V Relling
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

8.  An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing.

Authors:  M Bunke; R Sloan; M Brier; B Ganzel
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

9.  Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.

Authors:  Limin X Clegg; Frederick P Li; Benjamin F Hankey; Kenneth Chu; Brenda K Edwards
Journal:  Arch Intern Med       Date:  2002-09-23

10.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08
View more
  40 in total

Review 1.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

3.  Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.

Authors:  Mizuki Akahori; Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Wei Zhou; Gangadhar Sunkara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

4.  Research Professionals' Perspectives, Barriers, and Recommendations Regarding Minority Participation in Clinical Trials.

Authors:  Anita Kurt; Lauren Semler; Matthew Meyers; Bernadette G Porter; Jeanne L Jacoby; Brian Stello
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-21

5.  Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.

Authors:  Hyeong-Seok Lim; Jeong-Soo Im; Joo-Youn Cho; Kyun-Seop Bae; Terry A Klein; Joon-Sup Yeom; Tae-Seon Kim; Jae-Seon Choi; In-Jin Jang; Jae-Won Park
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

6.  Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.

Authors:  Natasa Djordjevic; Roza Ghotbi; Leif Bertilsson; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2007-12-22       Impact factor: 2.953

7.  Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.

Authors:  Patrick A Coffie; Besigin Tonwe-Gold; Aristophane K Tanon; Clarisse Amani-Bosse; Gédéon Bédikou; Elaine J Abrams; François Dabis; Didier K Ekouevi
Journal:  BMC Infect Dis       Date:  2010-06-24       Impact factor: 3.090

Review 8.  Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder?

Authors:  Changsu Han; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 9.  Liver transplantation in the ethnic minority population: challenges and prospects.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Dig Dis Sci       Date:  2009-04-24       Impact factor: 3.199

10.  Global variation in CYP2C8-CYP2C9 functional haplotypes.

Authors:  William C Speed; Soonmo Peter Kang; David P Tuck; Lyndsay N Harris; Kenneth K Kidd
Journal:  Pharmacogenomics J       Date:  2009-04-21       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.